Paper2736308
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B and 5 others. Blut, 1989. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Papers, record 2736308. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2736308
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydroxyurea | Major topic |
| Interferon Type I | Major topic |
| Interferon-alpha | Major topic |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | |
| Drug Evaluation | |
| Humans | |
| Interferon alpha-2 | |
| L-Lactate Dehydrogenase | |
| Leukocyte Count | |
| Philadelphia Chromosome | |
| Platelet Count | |
| Recombinant Proteins |
Source PubMed
References10
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6956430 | Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. | Cancer | 1982 | https://conductscience.org/library/papers/6956430 | PubMed |
| 2 | 3457264 | Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. | N Engl J Med | 1986 | https://conductscience.org/library/papers/3457264 | PubMed |
| 3 | 3471281 | Clinical investigation of human alpha interferon in chronic myelogenous leukemia. | Blood | 1987 | https://conductscience.org/library/papers/3471281 | PubMed |
| 4 | 3277680 | Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. | Blut | 1988 | https://conductscience.org/library/papers/3277680 | PubMed |
| 5 | 3516621 | [alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia]. | Dtsch Med Wochenschr | 1986 | https://conductscience.org/library/papers/3516621 | PubMed |
| 6 | 6952759 | Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. | Am J Clin Oncol | 1982 | https://conductscience.org/library/papers/6952759 | PubMed |
| 7 | 3166389 | Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients. | Blut | 1988 | https://conductscience.org/library/papers/3166389 | PubMed |
| 8 | 2450402 | Therapy of chronic myelogenous leukemia: chemotherapy and interferons. | Semin Hematol | 1988 | https://conductscience.org/library/papers/2450402 | PubMed |
| 9 | 3115339 | Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. | Blood | 1987 | https://conductscience.org/library/papers/3115339 | PubMed |
| 10 | 3165298 | Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. | Blood | 1988 | https://conductscience.org/library/papers/3165298 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 28624910 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? | J Cancer Res Clin Oncol | 2017 | https://conductscience.org/library/papers/28624910 | PubMed |
| 27057468 | Trial Watch-Immunostimulation with cytokines in cancer therapy. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/27057468 | PubMed |
| 25083328 | Trial watch: Immunostimulatory cytokines in cancer therapy. | Oncoimmunology | 2014 | https://conductscience.org/library/papers/25083328 | PubMed |
| 19959212 | The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/19959212 | PubMed |
| 12886239 | Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. | Leukemia | 2003 | https://conductscience.org/library/papers/12886239 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2736308
GET https://conductscience.org/api/papers/v1/2736308/authors